Market Closed -
Hong Kong S.E.
09:08:22 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
4.04
HKD
|
+0.25%
|
|
+0.25%
|
-12.55%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,312
|
1,072
|
1,720
|
3,696
|
Enterprise Value (EV)
1 |
1,391
|
1,239
|
1,987
|
3,863
|
P/E ratio
|
-19.7
x
|
-55.5
x
|
38.4
x
|
12.2
x
|
Yield
|
-
|
-
|
1.4%
|
1.52%
|
Capitalization / Revenue
|
2.59
x
|
1.21
x
|
1.45
x
|
3.08
x
|
EV / Revenue
|
2.75
x
|
1.39
x
|
1.68
x
|
3.22
x
|
EV / EBITDA
|
-37.4
x
|
112
x
|
25.6
x
|
28
x
|
EV / FCF
|
-24.9
x
|
-26.1
x
|
-24.8
x
|
54
x
|
FCF Yield
|
-4.02%
|
-3.83%
|
-4.03%
|
1.85%
|
Price to Book
|
4.55
x
|
4.16
x
|
5.86
x
|
6.89
x
|
Nbr of stocks (in thousands)
|
800,000
|
800,000
|
800,000
|
800,000
|
Reference price
2 |
1.640
|
1.340
|
2.150
|
4.620
|
Announcement Date
|
22/04/21
|
21/04/22
|
13/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
693.3
|
700.8
|
506
|
888.9
|
1,186
|
1,199
|
EBITDA
1 |
137.7
|
90.51
|
-37.18
|
11.07
|
77.69
|
138.1
|
EBIT
1 |
135.5
|
86.37
|
-41.79
|
4.333
|
70.49
|
130.3
|
Operating Margin
|
19.54%
|
12.33%
|
-8.26%
|
0.49%
|
5.94%
|
10.87%
|
Earnings before Tax (EBT)
1 |
123.7
|
68.36
|
-68.47
|
-17.5
|
50.37
|
317.7
|
Net income
1 |
100.9
|
54.52
|
-61.13
|
-18.82
|
43.75
|
297.3
|
Net margin
|
14.55%
|
7.78%
|
-12.08%
|
-2.12%
|
3.69%
|
24.8%
|
EPS
|
-
|
1.379
|
-0.0834
|
-0.0241
|
0.0560
|
0.3800
|
Free Cash Flow
1 |
37.04
|
65.97
|
-55.95
|
-47.51
|
-80.05
|
71.47
|
FCF margin
|
5.34%
|
9.41%
|
-11.06%
|
-5.34%
|
-6.75%
|
5.96%
|
FCF Conversion (EBITDA)
|
26.91%
|
72.89%
|
-
|
-
|
-
|
51.75%
|
FCF Conversion (Net income)
|
36.71%
|
121.01%
|
-
|
-
|
-
|
24.04%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
0.0300
|
0.0700
|
Announcement Date
|
30/03/20
|
30/03/20
|
22/04/21
|
21/04/22
|
13/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
131
|
116
|
79
|
167
|
267
|
167
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.955
x
|
1.284
x
|
-2.124
x
|
15.13
x
|
3.437
x
|
1.21
x
|
Free Cash Flow
1 |
37
|
66
|
-56
|
-47.5
|
-80.1
|
71.5
|
ROE (net income / shareholders' equity)
|
85.1%
|
46.9%
|
-29.8%
|
-6.31%
|
15.7%
|
71.1%
|
ROA (Net income/ Total Assets)
|
27.3%
|
14.5%
|
-5.3%
|
0.36%
|
4.65%
|
8.14%
|
Assets
1 |
370.1
|
376.1
|
1,154
|
-5,217
|
940.2
|
3,652
|
Book Value Per Share
|
-
|
2.990
|
0.3600
|
0.3200
|
0.3700
|
0.6700
|
Cash Flow per Share
|
-
|
1.280
|
0.1500
|
0.0900
|
0.0900
|
0.0500
|
Capex
1 |
34.2
|
5.23
|
11.4
|
7.91
|
1.46
|
3.88
|
Capex / Sales
|
4.93%
|
0.75%
|
2.26%
|
0.89%
|
0.12%
|
0.32%
|
Announcement Date
|
30/03/20
|
30/03/20
|
22/04/21
|
21/04/22
|
13/04/23
|
12/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -12.55% | 412M | | +16.01% | 71.39B | | +1.69% | 25.1B | | -1.22% | 8.59B | | +7.95% | 8.19B | | -20.48% | 7.91B | | +15.26% | 4.31B | | -1.24% | 3.93B | | -3.02% | 3.86B | | +21.10% | 3.64B |
Pharmaceuticals Wholesale
|